LADENBURG, Germany, June 06, 2025 (GLOBE NEWSWIRE) -- Heidelberg Pharma AG (XETRA: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that Andreas Pahl, CEO of Heidelberg Pharma, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on June 12th, 2025.
Heidelberg Pharma’s lead candidate, HDP-101, a BCMA-targeting ADC with the novel payload Amanitin, is being evaluated in a Phase I/IIa clinical trial for the treatment of relapsed or refractory Multiple Myeloma. HDP-101 is showing promising results, including a prolonged complete response in a patient who had undergone extensive prior treatment. The patient has received continuous treatment with HDP-101 alone for over 19 months, showing excellent tolerability of the drug.
In addition, promising biological activity and objective improvements were observed in several patients, underscoring the potential of HDP-101 as a treatment option for Multiple Myeloma. Dose escalation is continuing, and the study is advancing in cohort 8.
Furthermore, the second candidate, HDP-102, a CD-37-targeting ADC with the novel payload Amanitin, has recently entered clinical development and the first patient has been dosed in a Phase I study for the treatment of non-Hodgkin lymphoma (NHL).
DATE: June 12th
TIME: 10:00 AM ET
LINK: REGISTER HERE
Available for 1x1 meetings: June 12th and 13th
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com.
Recent Company Highlights
- Heidelberg Pharma Announced First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma
- Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
- PR: Heidelberg Pharma Amended Royalty Financing with HealthCare Royalty
About Heidelberg Pharma
Heidelberg Pharma is a biopharmaceutical company working on a new treatment approach in oncology and developing novel drugs based on its ADC technologies for the targeted and highly effective treatment of cancer. ADCs are antibody-drug conjugates that combine the specificity of antibodies with the efficacy of toxins to fight cancer. Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, that are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells.
Heidelberg Pharma uses several compounds and has built up an ADC toolbox that overcomes tumor resistance via numerous pathways and addresses different types of cancer using various antibodies. The goal is to develop targeted and highly effective ADCs for the treatment of a variety of malignant hematologic and solid tumors.
Heidelberg Pharma is the first company to use the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin represents a new therapeutic modality and is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology.
The company is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com.
ATAC® is a registered trademark of Heidelberg Pharma Research GmbH. ITAC™, ETAC™ are pending trademark applications of Heidelberg Pharma Research GmbH.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
CONTACTS:
Heidelberg Pharma AG
Sylvia Wimmer
Director Corporate Communications
Tel.: +49 89 41 31 38-29
E-mail: investors@hdpharma.com
Gregor-Mendel-Str. 22, 68526 Ladenburg
Virtual Investor Conferences
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com
